Olema Pharmaceuticals Inc

OLMA is in a Stage 2 advancing uptrend with corrective base formation. Medium-term bias remains bullish underpinned by rising short-term EMAs and supportive volume structure. Short-term timing is favorable as price is holding just above its rising 9 and 20 EMAs without exhaustion, presenting a low-risk entry opportunity near dynamic support zones.

• ↑Added to Russell Small Cap and 2500 Growth, raising institutional visibility
• ↑Palazestrant lead candidate addresses hormone-receptor-positive breast cancer segment
• ↓Severely negative earnings yield highlights return generation issues